Home  //  Scientific papers  //  Epigenetics  //  GLAD-PCR Assay of DNA Methylation Markers Associated with Colorectal Cancer

GLAD-PCR Assay of DNA Methylation Markers Associated with Colorectal Cancer

Alexey A. Evdokimov , Nina A. Netesova , Natalia A. Smetannikova , Murat A. Abdurashitov, Alexandr G. Akishev , Boris S. Malyshev , Evgeniya S. Davidovich , Vladimir V. Fedotov , Vitaliy V. Kuznetsov , Yuriy D. Ermolaev , Andrey B. Karpov , Alexey E. Sazonov , Ravil M. Tahauov , Sergey Kh. Degtyarev
Biol Med (Aligarh) , 8:7(2016)

Hypermethylation of the gene regulatory regions is documented for many cancer diseases. Such an aberrant DNA methylation in cancer cells is catalyzed by DNA methyltransferases Dnmt3a and Dnmt3b, which predominantly recognize and methylate RCGY sequences with formation of R(5mC)GY sites. Recently, based on a new methyl-directed DNA endonuclease GlaI, we developed a GLAD-PCR assay, which allows determining R(5mC)GY site in a defi ned position of the genomic DNA. In this work we applied GLAD-PCR assay for identifi cation of the methylated RCGY sites in the regulatory regions of some downregulated genes associated with colorectal cancer (CRC). This list includes ADHFE1, ALX4, CNRIP1, EID3, ELMO1, ESR1, FBN1, HLTF, LAMA1, NEUROG1, NGFR, RARB, RXRG, RYR2, SDC2, SEPT9, SFRP2, SOCS3, SOX17, THBD, TMEFF2, UCHL1, and VIM genes. GLAD-PCR analysis of selected RCGY sites within the regulatory regions of some of these genes demonstrates a good prognostic potential with relatively high sensitivity and specifi city of CRC detection in tumor DNA

Read full text (pdf)